Title: | Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma |
Authors: | Osawa, Takahiro Browse this author →KAKEN DB |
Kojima, Takahiro Browse this author →KAKEN DB |
Hara, Tomohiko Browse this author |
Sugimoto, Mikio Browse this author →KAKEN DB |
Eto, Masatoshi Browse this author →KAKEN DB |
Takeuchi, Ario Browse this author →KAKEN DB |
Minami, Keita Browse this author |
Nakai, Yasutomo Browse this author |
Ueda, Kosuke Browse this author |
Ozawa, Michinobu Browse this author |
Uemura, Motohide Browse this author →KAKEN DB |
Miyauchi, Yasuyuki Browse this author |
Ohba, Kojiro Browse this author →KAKEN DB |
Suzuki, Toshiro Browse this author |
Anai, Satoshi Browse this author →KAKEN DB |
Shindo, Tetsuya Browse this author →KAKEN DB |
Kusakabe, Naohisa Browse this author |
Tamura, Keita Browse this author |
Komiyama, Motokiyo Browse this author |
Goto, Takayuki Browse this author →KAKEN DB |
Yokomizo, Akira Browse this author →KAKEN DB |
Kohei, Naoki Browse this author |
Kashiwagi, Akira Browse this author |
Murakami, Masaya Browse this author |
Sazuka, Tomokazu Browse this author →KAKEN DB |
Yasumoto, Hiroaki Browse this author →KAKEN DB |
Iwamoto, Hideto Browse this author →KAKEN DB |
Mitsuzuka, Koji Browse this author →KAKEN DB |
Morooka, Daichi Browse this author |
Shimazui, Toru Browse this author →KAKEN DB |
Yamamoto, Yoshiaki Browse this author |
Ikeshiro, Suguru Browse this author |
Nakagomi, Hiroshi Browse this author |
Morita, Ken Browse this author |
Tomida, Ryotaro Browse this author |
Mochizuki, Tango Browse this author |
Inoue, Takamitsu Browse this author →KAKEN DB |
Kitamura, Hiroshi Browse this author |
Yamada, Shuhei Browse this author |
Ito, Yoichi M. Browse this author |
Murai, Sachiyo Browse this author |
Nishiyama, Hiroyuki Browse this author →KAKEN DB |
Shinohara, Nobuo Browse this author →KAKEN DB |
Keywords: | axitinib |
metastatic |
prognostic factor |
renal cell carcinoma |
risk model |
Issue Date: | Jul-2020 |
Publisher: | John Wiley & Sons |
Journal Title: | Cancer science |
Volume: | 111 |
Issue: | 7 |
Start Page: | 2460 |
End Page: | 2471 |
Publisher DOI: | 10.1111/cas.14449 |
Abstract: | The present study aimed to evaluate the efficacy of the real-world use of axitinib and to develop a prognostic model for stratifying patients who could derive long-term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic renal cell carcinoma that had been treated with 1 or 2 systemic antiangiogenic therapy regimens at 1 of 36 hospitals belonging to the Japan Urologic Oncology Group between January 2012 and February 2019. The primary outcome was overall survival (OS). Using a split-sample method, candidate variables that exhibited significant relationships with OS were chosen to create a model. The new model was validated using the rest of the cohort. In total, 485 patients were enrolled. The median OS was 34 months in the entire study population, whereas it was not reached, 27 months, and 14 months in the favorable, intermediate, and poor risk groups, respectively, according to the new risk classification model. The following 4 variables were included in the final risk model: the disease stage at diagnosis, number of metastatic sites at the start of axitinib therapy, serum albumin level, and neutrophil : lymphocyte ratio. The adjusted area under the curve values of the new model at 12, 36, and 60 months were 0.77, 0.82, and 0.82, respectively. The efficacy of axitinib in routine practice is comparable or even superior to that reported previously. The patients in the new model's favorable risk group might derive a long-term survival benefit from axitinib treatment. |
Rights: | https://creativecommons.org/licenses/by-nc/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/79043 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|